Functional significance of exosomes applied in sepsis: A novel approach to therapy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 1, 2017, Pages 292-297

  Wu, Jingjing ^a   Wang, Yini ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Biomarker; Drug vehicle; Exosome; miRNA; Sepsis

Indexed keywords

CURCUMIN; DRUG VEHICLE; FLUORESCENT DYE; MICRORNA; NANOPARTICLE; PROTEIN; SMALL INTERFERING RNA; DRUG CARRIER;

APOPTOSIS; BACTEREMIA; BACTERIAL PERITONITIS; CANCER CELL; CELL COMMUNICATION; CELL PROLIFERATION; DENDRITIC CELL; DONOR; DRUG DELIVERY SYSTEM; EXOSOME; EXPERIMENTAL MODEL; EXPERIMENTAL SEPSIS; GENE DELIVERY SYSTEM; HUMAN; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MESENCHYMAL STEM CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SEPSIS; ANIMAL; CELL FRACTIONATION; CHEMISTRY; GENETICS; METABOLISM; PROCEDURES; TRANSPLANTATION;

ANIMALS; CELL FRACTIONATION; DRUG CARRIERS; EXOSOMES; HUMANS; INFLAMMATION; MICRORNAS; SEPSIS;

EID: 84994765000     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.10.024     Document Type: Review

References (51)

1. [1] Chang, R., Holcomb, J.B., Choice of fluid therapy in the initial management of sepsis, severe sepsis, and septic shock. Shock 46:1 (2016), 17–26.
2. [2] Ayala*, A., M.P., Venet, F., Lomas-Neira, J., Swan, R., Chung, C.-S., Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. Curr. Pharma. Des. 14 (2008), 1853–1859.
3. [3] Marigo, I., Dazzi, F., The immunomodulatory properties of mesenchymal stem cells. Semin. Immunopathol. 33:6 (2011), 593–602.
4. [4] Nemeth, K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15:1 (2009), 42–49.
5. [5] Kusadasi, N., Groeneveld, A.B., A perspective on mesenchymal stromal cell transplantation in the treatment of sepsis. Shock 40:5 (2013), 352–357.
6. [6] Anderson, P., Souza-Moreira, L., Morell, M., Caro, M., O'Valle, F., Gonzalez-Rey, E., Delgado, M., Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 62 (2013), 1131–1141.
7. [7] Phinney, D.G., Prockop, D.J., Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells 25:11 (2007), 2896–2902.
8. [8] Srinivasan, S., Vannberg, F.O., Dixon, J.B., Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep., 6, 2016, 24436.
9. [9] Vlassov, A.V., et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 1820:7 (2012), 940–948.
10. [10] Johnsen, K.B., et al. A comprehensive overview of exosomes as drug delivery vehicles — endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846:1 (2014), 75–87.
11. [11] Ratajczak, J., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20:5 (2006), 847–856.
12. [12] Raposo, G., Stoorvogel, W., Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200:4 (2013), 373–383.
13. [13] Szatanek, R., et al. Isolation of extracellular vesicles: determining the correct approach (review). Int. J. Mol. Med. 36:1 (2015), 11–17.
14. [14] Clayton, A., et al. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunol. 33:2 (2003), 522–531.
15. [15] Suresh Mathivanan, J.W.E.L., Tauro, B.J., Ji, H., Moritz, R.L., Simpson, R.J., Proteomics analysis of A33 immuno affinity purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol. Cell. Proteomics 9 (2010), 197–208.
16. [16] Ren, J., et al. From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater. Sci. 4:6 (2016), 910–921.
17. [17] Yao, Y., et al. Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J. Biomed. Sci., 16, 2009, 74.
18. [18] McDonald, M.K., et al. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain 155:8 (2014), 1527–1539.
19. [19] Cavalieri, D., et al. Plant microRNAs as novel immunomodulatory agents. Sci. Rep., 6, 2016, 25761.
20. [20] Miksa, M., et al. Immature dendritic cell-derived exosomes rescue septic animals via milk fat globule epidermal growth factor-factor VIII [corrected]. J. Immunol. 183:9 (2009), 5983–5990.
21. [21] Momen-Heravi, F., et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine 10:7 (2014), 1517–1527.
22. [22] Teng, H., et al. Suppression of inflammation by tumor-derived exosomes: a kind of natural liposome packaged with multifunctional proteins. J. Liposome Res. 22:4 (2012), 346–352.
23. [23] Soldevilla, B., et al. Tumor-derived exosomes are enriched in DeltaNp73, which promotes oncogenic potential in acceptor cells and correlates with patient survival. Hum. Mol. Genet. 23:2 (2014), 467–478.
24. [24] Choi, H., Lee, D.S., Illuminating the physiology of extracellular vesicles. Stem Cell Res. Ther., 7(1), 2016, 55.
25. [25] van Koppen, A., et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS One, 7(6), 2012, e38746.
26. [26] Xin, H., et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells 31:12 (2013), 2737–2746.
27. [27] Li, T., et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 22:6 (2013), 845–854.
28. [28] Lee, C., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126:22 (2012), 2601–2611.
29. [29] Zhuang, X., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 19:10 (2011), 1769–1779.
30. [30] Sun, D., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18:9 (2010), 1606–1614.
31. [31] Li, L., Zhang, L., Knez, M., Comparison of two endogenous delivery agents in cancer therapy: exosomes and ferritin. Pharmacol. Res. 110 (2016), 1–9.
32. [32] Alexander, M., et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat. Commun., 6, 2015, 7321.
33. [33] Villarroya-Beltri, C., et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun., 4, 2013, 2980.
34. [34] Ti, D.D., et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J. Transl. Med., 13, 2015, 14.
35. [35] Li, X., et al. Exosome derived from human umbilical cord mesenchymal stem cell mediates MiR-181c attenuating burn-induced excessive inflammation. EBioMedicine 8 (2016), 72–82.
36. [36] Webb, J.T., Behar, M., Topology, dynamics, and heterogeneity in immune signaling. Wiley Interdiscip. Rev. Syst. Biol. Med. 7:5 (2015), 285–300.
37. [37] Wang, X., et al. Exosomal miR-223 contributes to mesenchymal stem cell-elicited cardioprotection in polymicrobial sepsis. Sci. Rep., 5, 2015, 13721.
38. [38] O'Connell, R.M., et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33:4 (2010), 607–619.
39. [39] Villarroya-Beltri, C., et al. Sorting it out: regulation of exosome loading. Semin. Cancer Biol. 28 (2014), 3–13.
40. [40] Perez-Hernandez, D., et al. The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. J. Biol. Chem. 288:17 (2013), 11649–11661.
41. [41] Ha, D., Yang, N., Nadithe, V., Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm. Sin. B 6:4 (2016), 287–296.
42. [42] Miyasaka, K., et al. Expression of milk fat globule epidermal growth factor 8 in immature dendritic cells for engulfment of apoptotic cells. Eur. J. Immunol. 34:5 (2004), 1414–1422.
43. [43] Matsuda, A., Jacob, A., Wu, R., Aziz, M., Yang, W.-L., Matsutani, T., Suzuki, H., Furukawa, K., Uchida, E., Wang, P., Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. J. Nippon Med. Sch., 79(1), 2012.
44. [44] Wang, X., et al. Molecular mechanisms underlying the regulation of the MFG-E8 gene promoter activity in physiological and inflammatory conditions. J. Cell. Biochem. 116:9 (2015), 1867–1879.
45. [45] Miksa, M., et al. Dendritic cell-derived exosomes containing milk fat globule epidermal growth factor-factor VIII attenuate proinflammatory responses in sepsis. Shock 25:6 (2006), 586–593.
46. [46] Haney, M.J., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 207 (2015), 18–30.
47. [47] Lai, R.C., et al. Exosomes for drug delivery — a novel application for the mesenchymal stem cell. Biotechnol. Adv. 31:5 (2013), 543–551.
48. [48] Fuhrmann, G., Herrmann, I.K., Stevens, M.M., Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10:3 (2015), 397–409.
49. [49] Pecot, C.V., et al. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11:1 (2011), 59–67.
50. [50] Burnett, J.C., Rossi, J.J., RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19:1 (2012), 60–71.
51. [51] Peterson, M.F., et al. Integrated systems for exosome investigation. Methods 87 (2015), 31–45.